Developing a treatment for Nipah Virus infection
Preclinical development of a Nipah Virus inhibitor
This study is looking at a potential new treatment for Nipah Virus using a medicine called pyronaridine, which has shown promise against other viruses, to see if it can help keep people safe and healthy if they get infected.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Collaborations Pharmaceuticals, INC. NIH-funded |
| Lab location | 1 site (Fuquay Varina, United States) |
| Project ID | NIH-10761349 on NIH RePORTER |
What this research studies
This research focuses on creating an effective antiviral treatment for Nipah Virus, a severe and often fatal disease transmitted from bats to humans. The team is investigating the antiviral properties of a compound called pyronaridine, which has shown promise against various viruses, including Ebola and SARS-CoV-2. The research involves testing the maximum tolerated dose and how the drug is processed in the body, aiming to establish a safe and effective treatment option for this dangerous virus. By understanding how pyronaridine works, the researchers hope to provide a new therapeutic option for patients affected by Nipah Virus.
Who could benefit from this research
Good fit: Ideal candidates for this research would include individuals at risk of Nipah Virus infection, particularly those in regions where the virus is prevalent.
Not a fit: Patients who are not at risk of Nipah Virus infection or those with other unrelated health conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a new treatment for Nipah Virus, potentially saving lives and reducing the severity of the disease.
How similar studies have performed: Previous research has shown success with antiviral compounds like pyronaridine against other viruses, indicating potential for this approach.
Where this research is happening
Fuquay Varina, United States
- Collaborations Pharmaceuticals, INC. — Fuquay Varina, United States (Active)
Researchers
- Principal investigator: Ekins, Sean — Collaborations Pharmaceuticals, INC.
- Study coordinator: Ekins, Sean
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.